Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
143 Cards in this Set
- Front
- Back
MOA of quinolones
|
Inhibit DNA gyrase
|
|
MOA of penicillin
|
Block cell wall synthesis by inhibiting peptidoglycan cross-linkage
|
|
Drug used for MRSA
|
Vancomycin
|
|
Vancomycin MOA
|
Blocks peptidoglycan synthesis
|
|
Type of resistance found with vancomycin
|
Point mutation
|
|
Meningitis prophylaxis in exposed patients
|
Rifampin
|
|
Technique used to diagnose perianal itching, and the drug used to treat it
|
"Scotch tape technique and mebendazole
|
|
Two toxicities of aminoglycosides
|
nephro and ototoxicity
|
|
DOC for Legionnaires' disease
|
Erythromycin
|
|
MOA of sulfonamides
|
Inhibit dihydropteroate synthase
|
|
Penicillins active against penicillinase secreting bacteria
|
Methicillin, nafcillin, and dicloxacillin
|
|
Cheap wide spectrum antibiotic DOC for otitis media
|
Amoxicillin
|
|
Class of antibiotics that have 10% cross sensitivity with penicillins
|
Cephalosporins
|
|
PCN active against pseudomonas
|
Carbenicillin, piperacillin and ticarcillin
|
|
Antibiotic causing red-man syndrome, and prevention
|
Vancomycin, infusion at a slow rate and antihistamines
|
|
Drug causes teeth discoloration
|
Tetracycline
|
|
MOA of tetracycline
|
Decreases protein synthesis by inhibiting 30S ribosome
|
|
Drug that causes gray baby syndrome and aplastic anemia
|
Chloramphenicol
|
|
Drug notorious for causing pseudomembranous colitis
|
Clindamycin
|
|
DOC for tx of pseudomembranous colitis
|
Metronidazole
|
|
Treatment of resistant pseudomembranous colitis
|
ORAL vancomycin
|
|
Anemia caused by trimethoprim
|
Megaloblastic anemia
|
|
Reason fluoroquinolones are contraindicated in children and pregnancy
|
Cartilage damage
|
|
DOC for giardia, bacterial vaginosis, pseudomembranous colitis, and trichomonas
|
Metronidazole
|
|
Treatment for TB patients (think RIPE)
|
Rifampin, Isoniazid, Pyrazinamide, and Ethambutol
|
|
Metronidazole SE if given with alcohol
|
Disulfiram-like reaction
|
|
Common side effect of Rifampin
|
Red urine discoloration
|
|
MOA of nystatin
|
Bind ergosterol in fungal cell membrane
|
|
Neurotoxicity with isoniazid (INH) prevented by
|
Administration of Vit. B6 (pyridoxine)
|
|
Toxicity of amphotericin
|
Nephrotoxicity
|
|
SE seen only in men with administration of ketoconazole
|
Gynecomastia
|
|
Topical DOC in impetigo
|
Topical mupirocin (Bactroban)
|
|
DOC for influenza A
|
Amantadine
|
|
DOC for RSV
|
Ribavirin
|
|
DOC for CMV retinitis
|
Ganciclovir
|
|
SE for ganciclovir
|
Neutro, leuko and thrombocytopenia
|
|
Anti-viral agents associated with Stephen Johnson syndrome
|
Nevirapine, amprenavir
|
|
HIV antiviral class known to have severe drug interactions by causing inhibition of metabolism
|
Protease inhibitors
|
|
Antivirals that are teratogens
|
Delavirdine, efavirenz, and ribavirin
|
|
Antivirals associated with neutropenia
|
Ganciclovir, zidovudine, saquinavir, and interferon
|
|
HIV med used to reduce transmission during birth
|
AZT (zidovudine)
|
|
Drug used for African sleeping sickness
|
Suramin
|
|
Drug used in Chagas disease
|
Nifurtimox
|
|
Cephalosporins able to cross the BBB
|
Cefuroxime (2nd) generation and Cefixime (3rd) generation
|
|
Drug used for N. gonorrhea in females
|
Ceftriaxone
|
|
Cephalosporin causes kernicterus in neonates
|
Ceftriaxone or cefuroxime
|
|
SE of INH
|
Peripheral neuritis and hepatitis
|
|
Aminoglycoside that is least ototoxic
|
Streptomycin
|
|
Drug used in exoerythrocytic cycle of malaria
|
Primaquine
|
|
Oral antibiotic of choice for moderate inflammatory acne
|
Minocycline
|
|
Drug of choice for leprosy
|
Dapsone, rifampin and clofazimine combination
|
|
DOC for herpes and its MOA
|
Acyclovir; incorporated into viral DNA and chain termination
|
|
Anti-microbials that cause hemolysis in G6PD-deficient patients
|
Sulfonamides
|
|
MOA of erythromycin
|
Inhibition of protein synthesis at the 50s subunit of ribosome
|
|
Anti-biotic frequently used for chronic UTI prophylaxis
|
sulfamethoxazole/ trimethoprim
|
|
Lactam that can be used in PCN allergic patients
|
Aztreonam
|
|
SE of imipenem
|
Seizures
|
|
Anti-viral with a dose limiting toxicity of pancreatitis
|
Didanosine
|
|
chapter 46 TMP/SMX/fluorquinolones
|
|
|
sulfanomides are structurally similar to what chemical compound
|
PABA (p-aminobenzoic acid)
|
|
name the short, intermediate, and long acting sulfonamides
|
sulfisoxazole, sulfamethoxazole, sulfadoxine respectively
|
|
trimethoprim is structurally similar to what chemical compund?
|
folic acid
|
|
MOA of sulfonamides
|
competitive inhibitor of dihydropteroate synthase
|
|
MOA of trimethoprim
|
selective inhibition of dihydrofolate reductase
|
|
common mechanism of resistance to trimethoprim
|
production of dihydrofolate reductase w/ lower afinity for the drug
|
|
what is the importanc of folic acid?
|
it is required for the synthesis of purines
|
|
sulfonamides used for burn infections
|
mafenide or silver sulfasalazine
|
|
DOC for toxoplasmosis
|
sulfadiazine + pyrimethamine
|
|
DOC for p. pneumonia infection in immunocompromised pts?
|
TMP-SMX
|
|
DOC for nocardiosis
|
TMP-SMX
|
|
SE of sulfonamides
|
allergic reaction, polyarteritis nodosa, Stevens-Johnsons syndrome, NVD, granulocytopenia, thrombocytopenia, aplastic anemia, hemolysis in pts w/ glucose-6-phosphate dehydrogenase deficency, crystalluria and hematuria from precipitation at low pH, transient increase in warfarin and methotrexate plasma lvls, risk of kernicterus of neonate if used in the 3rd trimester of pregnancy
|
|
SE of trimethoprim
|
Megaloblastic anemia, leukopenia, granulocytopenia
|
|
used to aleviate side effects for therapy
|
folinic acid
|
|
name the fluoroquinolones
|
norfloxacin, ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, gemifloxacin, moxifloxicin
|
|
renal excretion of fluroquinolones can be blocked by what?
|
probenecid
|
|
MOA of fluroquinolones
|
inhibition of topoisomerase II (DNA gyrase) especially in gram negative bacteria, and topoisomerase IV especially in gram positive bacteria
|
|
SE of fluroquinolones
|
rash, headache, dizzyness, insomnia, abnormal LFTs, phototoxicity, tendinitis, opportunistic infection by C. albicans, not recommended for children or in pregnancy because of cartilage problems
|
|
SE of newer fluoroqunolones (gemifloxacin, levofloxacin, moxifloxacin)
|
QTc prolongation
|
|
antiviral drugs which blocks viral penitration and uncoating
|
amantadine, rimantadine
|
|
antiviral drugs which inhibit viral DNA polymerase
|
acyclovir, foscarnet, gancyclovir
|
|
antiviral drugs which inhibit viral RNA polymerases
|
foscarnet, ribavirin
|
|
antiviral drug which inhibits viral reverse transcriptase
|
zidovudine, didanosine, zalctibine, lamivudine, stavudine, nevirapine, delavirdine, efavirenz
|
|
antiviral drugs which inhibit viral aspartate protease (inhibit viral protein synthesis and processing)
|
indinavir, ritonavir, saquinavir, nelfinavir
|
|
antiviral drugs which inhibit viral neuraminidase (inhibit viral assembly and release)
|
zanamivir, oseltamivir
|
|
antiviral drug which is phosphorylated by viral thymidine kinase (TK)
|
acyclovir
|
|
acyclovir is used for the Tx of what?
|
HSV, VSV
|
|
SE of acyclovir
|
not hematotoxic, SE include crystalluria
|
|
drug used for prophylaxis of CMV infection
|
ganciclovir
|
|
ganciclovir has activity against what infections
|
|
|
SE of ganciclovir
|
hepatotoxicity, bonemarrow supression, seizures in overdose
|
|
drug used for TK- HSV (HSV strains which lack thymidine kinase)
|
foscarnet
|
|
SE of foscarnet
|
not hepatotoxic and will not cause bone marrow supression, nephrotoxicity, hypocalcemia (tremors, seizures), do not use with pentamidine
|
|
foscarnet is used for what infections
|
CMV, HSV, VSV?
|
|
what is HAART?
|
highly active anti-retroviral therapy; use of a combination of three drugs from the classes NRTI, NNRTI, and PI (usually 2NRTIs + PI)
|
|
what is the difference between NRTIs and NNRTIs, and so are not myelosuppressive, they bind to a different site than the NRTIs
|
NNRTIs do not require metabolic activation
|
|
what is reverse transcriptase?
|
RNA dependant DNA polymerase
|
|
drug interactions of AZT (zidovudine)
|
drug levels of ZDV are increased by azoles and cimetidine (inhibitors of P450), indomethacin and probenecid (decrease renal clearance), and TMP-SMX (additive meyleosupressive effect) ; drug levels are descrease by rifampin (inducers of P450)
|
|
SE of AZT (ZVD)
|
hematotoxicity, headache, myalgia, myopathy, peripheral neuropathy, lactic acidosis
|
|
difference between AZT and newer NRTIs?
|
newer NRTIs have less bone marrow supressing effects
|
|
SE of didanosine (DDI)?
|
Pancreatitis, peripheral neuropathy, hyperuricemia, liver dysfunction
|
|
SE of zalcitabine (DDC)
|
peripheral neuropathy, Pancreatitis, neutropenia (don't give with DDI)
|
|
why shouldn't you use AZT with stavudine (D4T)?
|
D4T is an AZT analog, and they compete for the same binding site
|
|
what is the least toxic of the NRTIs?
|
lamivudine (3TC), but it is very weakly effective on HIV so should be used only in combination with other drugs
|
|
what NRTI can also be used for HBV infection?
|
lamivudine (3TC)
|
|
what is the mechanism of resistance to protease inhibitors?
|
mutations in the pol gene
|
|
SE of indinavir
|
nephrolithiasis (maintain hydration), GI distress, thrombocytopenia, inhibition of P450(3A4)
|
|
SE of ritonavir
|
major drug interactions: induces CYP1A2, and inhibits CYP3A4 and CYP2D6, as well as disordered lipid and carbohydrate metabolism, asthenia and paresthesias
|
|
MOA of enfurvitide
|
fusion inhibitor- binds gp41
|
|
what is the MOA, uses, and SE of amantadine?
|
blocks attachment, penetration, and uncoating of influenza A virus, SE: atropine-like effects (antimuscarinic)
|
|
MOA, use, and SE of zanamivir and oseltamivir
|
inhibit influenzae A and B neuraminidases (prevent budding), N&V, nasal and throat irritations (zanamivir)
|
|
MOA, use, and SE of ribavirin
|
inhibits the synthesis of purines and viral RNA polymerase and end-capping, use: usually RSV, but also influenzae A and B, lassa fever, hantavirus, HCV (w/interferon alpha), SE: hematotoxic, teratogenic, respiratory irritaton
|
|
drugs which are used for HBV, HCV, HDV, Kaposi sarcoma, CML, multiple myeloma, renal carcinoma, and MS
|
interferons
|
|
what is the primary drug Tx for CMV
|
ganciclovir or valganciclovir
|
|
what is the primary drug Tx for HSV and VSV
|
acyclovir
|
|
what is the primary drug Tx for HBV
|
INF-a or lamivudine
|
|
what is the primary drug Tx for HCV
|
INF-a
|
|
what is the primary drug Tx for influenza A
|
oseltamivir
|
|
what is the primary drig Tx for influenza B
|
oseltamivir
|
|
is the amount of time above the MIC important for aminoglycosides?
|
no
|
|
how are amino glycosides administered and why
|
IV or IM because they are not absorbed oraly
|
|
elimination of aminoglycosides is via what mechanism?
|
glomerular filtration
|
|
MOA of aminoglycosides
|
bind to 30s subunit and block formation of the initiation complex, cause misreading of mRNA, and inhibit translocation
|
|
major mechanism of resistance to aminoglycosides?
|
plasmid mediated inactivating enzymes (group tansferases)
|
|
aminoglycosides work better on aerobes or anareobes?
|
areobes because penitration is partially oxygen dependant
|
|
amino glycosides restricted to topical or oral uses?
|
neomycin and kanamycin
|
|
aminoglycoside -like drug used for the Tx of penicillin allergic gonorhea pts
|
spectinomycin
|
|
SE of amino glycosides
|
ototoxicity (contraindicated in pregnancy), nephrotoxicity, neuromuscular blockade (reversable by Ca + neostigmine)
|
|
most nephrotoxic aminoglycosides
|
gentamicin and tobramycin
|
|
amino glycosides used systemically
|
gentamicin, amikacin, netilmicin, tobramycin
|
|
pharm 47 antimycobacterial
|
|
|
MOA of INH
|
structural cogener of B6 (pyridoxine), inhibits mycolic acids (compenents of mycobacterial cell walls)
|
|
what TB drug is usually given for prophylaxis of TB
|
INH
|
|
neurotoxic effects of INH can be elieviated by adminitering what?
|
B6 (pyridoxine)
|
|
what genetic disorder is associated with hemolysis when taking INH?
|
pts w/ glucose-6-phosphate dehydrogenase deffiency
|
|
MOA of rifampin
|
inhibition of DNA-dependant RNA polymerase
|
|
major SE of rifampin
|
induction of drug metabolizing liver enzymes, increasing the elimination of anticonvulsants, contraceptives, cyclosporine, ketoconazole, methadone, terbinafine, and warfarin
|
|
MOA of ethambutol
|
inhibition of arabinosyl transferase (arabinogalactan is a component of the mycobaterial cell wall)
|
|
SE of ethambutol
|
visual disturbances
|
|
SE of pyrazinamide
|
polyarthralgia, porphyria, hepatic dysfuntion, should not be used in pregnancy
|
|
drug Tx for TB when INH resistance is suspected
|
rifampin + pyrazinamide + ethambutol or streptomycin
|
|
multi drug resistant TB can be treated with what drugs (based on susceptability)
|
amikacin, ciprofloxacin, ofloxacin, ethionamide, p-aminosalicylic acid (rarely)
|
|
usual drug Tx for M. leprae
|
Dapsone, rifampin and clofazimine combination
|
|
prophylaxis of MAC in AIDS pts w/ CD4 <50
|
clarythromycin or azithromycin with or without rifabutin
|